ChrysaLabs develops a portable probe that can measure in real-time soil nutrients and soil health for producers and agronomists. It also develops a management platform which enables workers to access data and take action. The company was founded in 2017 and is based in Montreal, Canada.
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.
Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).
Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).
9am.health redesigns all care elements into one digital service individualized around today’s reality of people’s life - always available and convenient, at prices anyone can afford even without insurance. 9am.health focuses on chronic conditions such as diabetes, hypertension, and hyperlipidemia for customers in the United States.
Apollo Agriculture, founded in 2015 and based in Nairobi, Kenya, focuses on providing financial and technical support to smallholder farmers in emerging markets. The company offers farming loans to help farmers purchase essential inputs such as fertilizer, seeds, and crop insurance, along with access to expert consultations via mobile technology. By utilizing agronomic machine learning and remote sensing, Apollo tailors its services to individual farmers, assessing credit risk and customizing packages based on satellite and soil data, as well as crop yield models. This approach not only enhances the effectiveness of farming practices but also aims to significantly increase yields and profits for farmers.
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
Woebot Health is a San Francisco-based company founded in 2017 that specializes in developing mental health chatbot applications. Its primary mission is to make mental health care widely accessible through innovative technology. The company's chatbot engages users in conversation, providing tailored responses to help reduce symptoms of mood-based disorders. By combining effective therapeutic techniques with advanced digital tools, Woebot Health offers a suite of digital therapeutics and behavioral health products designed to be responsive and targeted to individual needs. The company has received funding from several venture capital firms, including New Enterprise Associates, Jazz Venture Partners, and Social Discovery Ventures, as well as contributions from Andrew Ng's AI Fund.
Vivante Health, Inc. is a digital health company focused on addressing digestive health and chronic conditions. Founded in 2016, it has developed GIThrive, a technology platform designed to provide actionable insights for managing digestive issues. GIThrive offers a comprehensive digital gut health program that includes expert guidance, 24/7 support, and personalized care plans. The company also provides GIMate, an innovative portable breathalyzer that identifies trigger foods, and GutCheck, which analyzes gut bacteria to recommend tailored diets. Vivante Health emphasizes individualized care, utilizing a scalable platform that integrates real-time data from biometric devices and partners. This approach not only aims to reduce healthcare costs and improve employee health for large employers and health plans but also enhances user empowerment through advanced science and technology. Headquartered in Houston, Texas, with an additional office in Athens, Greece, Vivante Health continues to prioritize innovative solutions in the realm of digestive health.
Indapta Therapeutics is a privately held biotechnology company focused on developing a natural killer (NK) cell therapy platform aimed at treating both blood and solid tumor cancers. The company specializes in a proprietary off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the effectiveness of antibody therapies. Through its innovative approach, Indapta Therapeutics seeks to provide healthcare providers with advanced treatment options for patients suffering from cancer, leveraging the potent antibody-dependent cellular cytotoxicity (ADCC) activity of its NK cell therapy.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.
Gandeeva Therapeutics has developed a proprietary platform that combines innovative technologies across biochemistry, structural biology, imaging and machine learning to characterize protein-drug interactions at the atomic level, all designed to provide new insights into targeting protein function.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. The company specializes in developing intracellular delivery lasers and nanotechnology for gene editing applications. By leveraging advanced tools from optics, biology, and computation, Cellino transforms the process of stem cell differentiation into a digital format, allowing for the engineering of functionally mature cells. This innovative approach significantly accelerates the development time of engineered cells, reducing it from years to weeks.
Bloom Science, Inc. is a biotechnology company focused on developing neuroprotective medicines that leverage the microbiome to address epilepsy and other neurological disorders. Founded in 2017 and based in San Diego, California, the company aims to create genetically optimized microbes that can treat patients suffering from pharmacoresistant and underserved diseases. Bloom Science seeks to translate the therapeutic advantages of the ketogenic diet into innovative biopharmaceuticals, providing effective treatment options for individuals facing serious and life-altering neurological conditions.
MedArrive, Inc. owns and operates a software-as-a-service technology health platform. It enables healthcare providers to extend care services through integrated care management platform. It also integrates clinical data into electronic medical records software and provides communication and billing capabilities. The company is based in New York, New York.
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
Deka Biosciences
Series A in 2021
Early stage biotechnology start-up developing next generation cytokine therapeutics
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.
Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity.
The company was founded in 2013 and headquartered in Emeryville, California.
Andes develops technologies for a more sustainable and efficient agriculture. Our solutions are based on beneficial microbes that have naturally co-evolved through thousands of years with plants. Microbe-based formulations are customized through scientific research and an advanced predictive software using Artificial Intelligence. Our technology will allow farmers to have better yields, grow their crops faster, cultivate on traditionally unsuitable lands, use less fertilizers and pesticides, and successfully face the challenges of global climate change.
Microbe-based solutions have the potential to foster a new green revolution in a healthy, responsible and environmentally friendly way, and Andes plays a key role in this transformation.
Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.
Ada is a global health company founded by doctors, scientists, and industry pioneers to create new possibilities for personal health. Ada’s core system connects medical knowledge with intelligent technology to help all people actively manage their health and medical professionals to deliver effective care. Ada is proud to collaborate with leading health systems and global non-profit organizations to carry out this vision. The #1 medical app for 130 countries, almost 20 million assessments have been completed since its global launch in 2016.
Huma Therapeutics Limited is a healthcare technology company based in London, United Kingdom, focused on improving the lives of individuals with chronic, complex, and rare diseases. The company operates a healthcare platform that integrates patient data from various medical databases and devices, making it accessible to healthcare professionals. One of its key offerings is Medopad, a remote patient monitoring platform that allows doctors to oversee patients with conditions such as Covid-19 without the need for hospital admission. Huma collaborates with leading healthcare providers, pharmaceutical companies, insurers, and technology firms, including Apple and Tencent, to create a connected digital health ecosystem. Founded in 2011 and rebranded from Humaforhealth Limited in April 2020, Huma continues to expand its impact in the healthcare sector.
Edifice Health is a spin-out company from a 10-year research study on immune profiling from Stanford University, the Stanford 1,000 Immunomes Project. The technology is the first biomarker composite scoring system to measure immune health and the Inflammatory Age® of an individual which predicts the onset of multiple chronic diseases and provides comprehensive health insights designed to help people change the course of their aging process.
Guardian Agriculture designs and manufactures unmanned aerial vehicles (UAVs) equipped with global positioning system (GPS) technology for agricultural applications. Founded in 2017 and based in Malden, Massachusetts, the company offers aerial crop protection and spray services, utilizing its UAVs to apply insecticides, herbicides, fungicides, and liquid fertilizers. By leveraging advanced technology, Guardian Agriculture aims to enhance crop protection and improve agricultural efficiency.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Grão Direto LTDA operates a digital trading platform designed for the buying and selling of grains, facilitating interactions between farmers and grain buyers. Founded in 2016 and based in Uberaba, Brazil, the platform enhances market intelligence analysis, enabling users to make informed decisions regarding market rates and grain selection. It supports various trading types, including spot, future, and barter trades, while also streamlining associated processes such as logistics, contract management, and financial products. Grão Direto connects a diverse range of participants in the agricultural sector, including cooperatives, brokers, feed factories, and traders, promoting efficiency and agility in the grain trading process through modern technology.
Amfora is an emerging leader in the use of biotechnology to address the rapidly growing global demand for protein. Amfora is working to develop nutritionally enhanced forage crops for a market expected to have an annual value of as much as $12 billion a year. The company is based in San Francisco, California and is a portfolio company of Spruce Capital Partners LLC/MLS II Fund.
Pairwise, Inc. is a food and technology company focused on improving the quality of fruits and vegetables through innovative agricultural gene editing techniques. Founded in 2017 and based in San Diego, California, Pairwise collaborates with food and agriculture companies to develop new crop varieties, including leafy greens, berries, and stone fruits. The company utilizes advanced tools and traits licensed from Harvard and Massachusetts General Hospital, leveraging expertise from a team with backgrounds in agriculture, consumer packaged goods, and research. With a commitment to fostering a healthier world, Pairwise aims to introduce its first products in the coming years, contributing to advancements in food technology and sustainable agriculture.
Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders. The company's technology uses artificial intelligence, immunology, computational biology, and protein engineering to make safe proteins that do not trigger an immune response, enabling physicians to prescribe to people products that are safe to consume.
Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).
Rantizo delivers targeted liquid dry applications for agriculture precisely where and when they are needed in the field.The company's system utilizes an electrostatic spraying technology which reduces problems with uneven coverage and covers crops uniformly, enabling farmers to apply pesticides and chemicals in the farms evenly without a hassle and within a short duration of time.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Azitra Inc. is a clinical-stage medical dermatology company based in Farmington, Connecticut, that focuses on developing microbiome-based therapeutics for skin diseases. Established in 2014, the company utilizes extensive scientific knowledge of the skin microbiome to create innovative treatments for various adverse skin conditions. Its technology platform is built around a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis, developed in collaboration with researchers from Yale University and the Jackson Laboratory. Azitra aims to address unmet medical needs in dermatology through its novel product offerings.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.
Recursion Pharmaceuticals is a biotechnology company based in Salt Lake City. Recursion combines experimental biology, automation, and artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, and immunology. Recursion is aggressively leveraging technology to build a robust and reliable map of human cellular biology, which will enable a radical shift in the pace and scale at which new treatments will benefit patients.
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
Unfold focuses on innovating vegetable varieties that deliver optimized quality and sensory experience in the vertical farming industry. They combine leading seed genetics with the agronomic expertise to dramatically advance productivity, flavor, and other consumer preferences.
It was founded in 2020 and is headquartered in Sacramento, California.
Vesigen, Inc. is a biotechnology company focused on developing innovative therapeutic products that utilize extracellular vesicle delivery technology to target intracellular sites. Founded in 2020 and based in Cambridge, Massachusetts, the company employs its proprietary ARMMs technology to facilitate the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This approach aims to overcome the challenges associated with intracellular drug delivery, thereby broadening the range of potential druggable targets and enabling the creation of novel treatments for various diseases. Vesigen's mission is to address unmet medical needs through its advanced therapeutic solutions.
Apollo Agriculture, founded in 2015 and based in Nairobi, Kenya, focuses on providing financial and technical support to smallholder farmers in emerging markets. The company offers farming loans to help farmers purchase essential inputs such as fertilizer, seeds, and crop insurance, along with access to expert consultations via mobile technology. By utilizing agronomic machine learning and remote sensing, Apollo tailors its services to individual farmers, assessing credit risk and customizing packages based on satellite and soil data, as well as crop yield models. This approach not only enhances the effectiveness of farming practices but also aims to significantly increase yields and profits for farmers.
CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.
NewLeaf Symbiotics develops and commercializes the bacteria found in Pink Pigmented Facultative Methylotrophs. NewLeaf Symbiotics has also filed its own related patents and is actively developing new technologies related to PPFMs.
The Company is engaged in laboratory, greenhouse, and field product trials and expects to commercialize and license products beginning in 2014.
Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.